BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 27634656)

  • 21. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.
    Ng IO; Shek TW; Nicholls J; Ma LT
    J Gastroenterol Hepatol; 1998 Jan; 13(1):34-40. PubMed ID: 9737569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
    Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
    Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
    Terada T
    Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.
    Shibahara J; Hayashi A; Misumi K; Sakamoto Y; Arita J; Hasegawa K; Kokudo N; Fukayama M
    Am J Surg Pathol; 2016 May; 40(5):608-16. PubMed ID: 26735856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features.
    Fukukura Y; Taguchi J; Nakashima O; Wada Y; Kojiro M
    J Comput Assist Tomogr; 1997; 21(1):52-8. PubMed ID: 9022770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
    Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
    Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
    Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification.
    Jung DH; Hwang S; Hong SM; Chung YK; Song GW; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Park GC; Lee HC; Lim YS; Yu ES; Lee SG
    World J Surg; 2017 May; 41(5):1347-1357. PubMed ID: 27896409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
    Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
    Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.
    Sasaki M; Nitta T; Sato Y; Nakanuma Y
    Am J Clin Pathol; 2016 Jun; 145(6):815-25. PubMed ID: 27334809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study.
    Tickoo SK; Zee SY; Obiekwe S; Xiao H; Koea J; Robiou C; Blumgart LH; Jarnagin W; Ladanyi M; Klimstra DS
    Am J Surg Pathol; 2002 Aug; 26(8):989-97. PubMed ID: 12170085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
    Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
    Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
    J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinctive clinicopathological features and KRAS and IDH1/2 mutation status of cholangiolocellular carcinoma.
    Kusano H; Naito Y; Mihara Y; Kondo R; Ogasawara S; Akiba J; Nakashima O; Yano H
    Hepatol Res; 2020 Jan; 50(1):84-91. PubMed ID: 31733634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.
    Jarnagin WR; Weber S; Tickoo SK; Koea JB; Obiekwe S; Fong Y; DeMatteo RP; Blumgart LH; Klimstra D
    Cancer; 2002 Apr; 94(7):2040-6. PubMed ID: 11932907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.